Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that topical BPM31543 was safe, tolerable, and showed potential to reduce chemotherapy-induced alopecia at higher dosing levels among adult women with cancer receiving taxane-based chemotherapy.

In this study, treatment with the oral contraceptive containing 30 μg ethinyl oestradiol and 150 μg desogestrel significantly reduced androgen-dependent hair growth in hirsute women over one year.

This study found that bolandiol increased lean body mass and bone mineral density in castrate adult male rats, exhibiting tissue selectivity and acting through multiple receptor pathways with less potency compared to other androgens.

This study found that oral contraceptive pills containing cyproterone acetate and drospirenone were more effective at reducing hirsutism in women with PCOS than those containing levonorgestrel over a 6-month period.

This study found that the CDK4/6 inhibitor palbociclib may protect human hair follicles from the damaging effects of taxane chemotherapy by inducing G1 arrest in stem/progenitor cells.

This study assessed vitamin E and a combined oral contraceptive's impact on continuous light-induced PCOS in female rats, finding they reduced testosterone levels and modified oxidative stress, suggesting benefits via melatonin-related pathways.

This review found moderate to very low-quality evidence that spironolactone, flutamide, and cyproterone acetate combined with oral contraceptives may reduce hirsutism more effectively than placebo or metformin, though results vary among other treatments.

This review explores contraceptive options for women with polycystic ovary syndrome, emphasizing the need for tailored choices based on individual clinical, hormonal, and metabolic profiles, but reports no new clinical findings.

This study found that circ 0020938 suppresses hair follicle stem cell proliferation by interacting with the miR-142-5p/DSG4 axis, which aids in the hair follicle cycle's proper progression.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

This case report details a probable severe adverse event associated with ritlecitinib for alopecia areata, highlighting risks of pulmonary emboli, infection, atrial fibrillation, and acute kidney injury despite an absence of known risk factors.

This review explores current and emerging treatments for polycystic ovary syndrome, focusing on managing hyperandrogenism and cardiometabolic risk, but reports no new clinical results.

This study found that applying BPM 31543 twice daily was safe, well-tolerated, and showed signs of reducing chemotherapy-induced alopecia in women receiving taxane-based chemotherapy.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

This study found that a combination of spironolactone and oral contraceptive pills may improve hirsutism and hormonal profiles in women, although some experienced side effects such as persistent nausea.

In this study, patients with varying severities of acne, seborrhoea, and hirsutism responded differently to Cyproteronacetate and Ethinyloestradiol treatment, with improvement rates dependent on symptom severity and treatment duration.

In this study, novel substituted benzoyl benzoic acids and phenylacetic acids were potent and selective inhibitors of human steroid 5alpha-reductase type 2, with one compound showing promising bioavailability in rats for potential clinical evaluation.

This study observed that women using combined oral contraceptives experienced more nausea, vomiting, and hair loss, while those on Depo-Provera were more likely to gain weight.

Leuprolide may better manage cholesterol and blood pressure in PCOS than spironolactone.

This study found that both combined therapy with goserelin and oral contraceptives, and oral contraceptives alone, significantly reduced hair diameter in severe hirsutism without a significant difference between treatments.

This study found that a low-dose oral contraceptive containing dienogest provides effective contraception, improves cycle stability, and may reduce excessive scalp and skin oiliness, with high user satisfaction.

This study highlights a paradox where valproic acid, known for causing hair loss, may also promote hair growth when applied topically.

This study found that the oral JAK inhibitors ritlecitinib and brepocitinib were effective in maintaining hair regrowth in alopecia areata with continuous use, though efficacy decreased after withdrawal.

This study reported that newly synthesized nonsteroidal compounds were effective at inhibiting prostatic 5 alpha reductase isozyme 2, especially the compound with an N, N-diisopropylcarbamoyl substituent, suggesting potential for treating benign prostatic hyperplasia.

This study reports experience treating 140 women with hirsutism and other virilism signs using cyproterone acetate and ethinyl estradiol, focusing on those treated for over five months.

This study found that combining metformin and clomifene citrate improved pregnancy outcomes and reduced miscarriage rates in women with PCOS and infertility undergoing intrauterine insemination.

This study by Moussa et al. reported that bicalutamide may help reduce minoxidil-induced hypertrichosis in women with female pattern hair loss.